US FDA's Generics Program Reaches 'Steady State' Milestone
Executive Summary
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
You may also be interested in...
Generic Review At US FDA: Record Month Completes Approval Volume Recovery
With 96 full ANDA approvals and 30 tentative approvals, July was the most productive month since GDUFA launched.
Generics Office At US FDA Could Get New Director Before Uhl Departs
Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
Performance numbers are likely to fluctuate over the course of the program, but the rate of first-cycle approvals during the first month of the new user fee program is more than double the rate during the last year of the old iteration.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests: